Opinion|Videos|January 21, 2025
Discussing Treatment Options for BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how treatment decisions involve balancing clinical efficacy with financial considerations, noting that patients often prefer treatments with fewer office visits and minimal lifestyle disruption when presented with multiple effective options.
Advertisement
Episodes in this series
- What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies?
- With all the available treatments on market, what are your patient preferences when it comes to treatment experiences?
Advertisement
Related to this article
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5